Post by Ai Tour China

China has transformed its clinical-trial approval process, reducing review timelines from over a year in the pre-reform era to approximately 60 working days today, with 30-day pathways now available for selected innovative therapies. 📊 According to recent financial reports and investment data from  Goldman Sachs and ING, China now accounts for roughly half  of global pharmaceutical licensing-deal value by dollars. Key facts shaping the industry right now: • Innovent Biologics signed a $10.5B deal with Pfizer for  12 cancer drug projects. • Bristol Myers Squibb joined forces with China's Hengrui Pharma  in an alliance worth up to $15.2B. This massive surge in out-licensing shows that Western firms  are heavily relying on Chinese discovery pipelines to restock  their own patent portfolios. 📈 Technology has no borders, and neither should our curiosity. 🌟 At Ai Tour China - Experience the future, we believe that understanding the global AI landscape requires more than just data—it requires human  connection. 🤝 Our Mission: To educate people about AI and robotics. Let’s  explore, learn, and collaborate for a better and safer  future 🌏 #AiTourChina #HengruiPharma #Innovent #BiotechData #PharmaStocks